Barostim Baroreflex Activation Therapy now offered at Holy Cross Health
FORT LAUDERDALE, FL – Holy Cross Health now offers Barostim™ Baroreflex Activation Therapy, the world’s first FDA-approved heart failure device to use neuromodulation – the power of the brain and nervous system – to improve the symptoms of patients with systolic heart failure. This therapy was designed to treat heart failure patients who may not be receiving adequate symptom relief from medications alone.
Unlike other heart failure device therapies, Barostim contains no hardware in the heart or vasculature. It works by electrically stimulating baroreceptors – natural sensors located in the wall of the carotid artery – that tell the nervous system how to regulate heart, kidney and vascular function. These effects reduce the heart’s workload and help it pump more efficiently, helping to restore balance to the autonomic nervous system and improve the symptoms of heart failure. Barostim plus heart failure medications has been shown to improve exercise capacity, quality of life and NYHA class, helping patients return to their daily activities.¹
“At Holy Cross Health we continue to invest in innovative technologies to provide our patients with the highest level of medical care that will get them back on their feet and resuming normal life as quickly and fully as possible,” said Mark Doyle, president and chief executive officer at Holy Cross Health.